Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population

Acta Cardiologica

Volumn 65, Issue 6, 2010, Pages 681-691

  Likidlilid, Atip ^a   Akrawinthawong, Krittapoom ^a   Poldee, Saiphon ^a   Sriratanasathavorn, Charn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atherosclerosis; Coronary heart disease; Paraoxonase 1; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; THAILAND;

EID: 78751607776     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.1080/ac.65.6.2059866     Document Type: Article

References (47)

1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
2. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91.
3. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
4. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knockout/apolipoproteine knockout mice exhibit increased lipoproteinoxidation and atherosclerosis. J Biol Chem 2000; 275:17527-35.
5. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-90.
6. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, Liu G, Zhang R, Liu JJ, Stallcup WB, Zhou Z, Liu DP, Liang CC. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in apoe-null mice. Circ Res 2009; 104: 1160-8.
7. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
8. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229-35.
9. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252-7.
10. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU. Paraoxonase 192__gln/arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48: 623-7.
11. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (pon1) deficiency is associated with increased macrophage oxidative stress: Studies in pon1-knockout mice. Free Radic Biol Med 2003; 34: 774-84.
12. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
13. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004; 15: 399-404.
14. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type ii diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000; 98: 355-63.
15. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-9.
16. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-73.
17. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000; 149: 435-42.
18. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS. The gln-arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among chinese in taiwan. Atherosclerosis 1998; 141: 259-64.
19. Ansell BJ. Targeting the anti-inflammatory effects of highdensity lipoprotein. Am J Cardiol 2007; 100: n3-9.
20. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z, Shen Y, Qiang B, Gu D. Extensive association analysis between polymorphisms of pon gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003; 23: 328-34.
21. Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective northwick park heart study ii. Biochim Biophys Acta 2003; 1639: 203-12.
22. Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, Fito M, Covas MI, Marrugat J. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J Lipid Res 2002; 43: 713-20.
23. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1__gene pon-1 by fenofibrate and statins. Mol Pharmacol 2003; 63: 945-56.
24. Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (pparalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (pon 1) activity. J Physiol Pharmacol 2002; 53: 463-75.
25. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43__studies. Lancet 2004; 363: 689-95.
26. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis. Is the gene or the protein more important? Free Radic Biol Med 2004; 37: 1317-23.
27. Shin BS. Paraoxonase gene polymorphism in south-western Korean population. J Korean Med Sci 2009; 24: 561-6.
28. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (gln192-arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257-60.
29. Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B. Paraoxonase 1__status in the Thai population. J Hum Genet 2005; 50: 293-300.
30. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990; 36: 15-9.
31. Rea IM, McKeown PP, McMaster D, Young IS, Patterson C, Savage MJ, Belton C, Marchegiani F, Olivieri F, Bonafe M, Franceschi C. Paraoxonase polymorphisms pon1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol 2004; 39: 629-35.
32. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, Bonaiuto A, Saitta C, Bitto A, Manduca B, Riggio S, Saitta A. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004; 39: 1089-94.
33. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-80.
34. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: Possible role for its phospholipase-a2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-7.
35. Chambers JE. Pon1__multitasks to protect health. Proc Natl Acad Sci USA 2008; 105: 12639-40.
36. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (humpona) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-8.
37. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
38. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (pon1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 1265-76.
39. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (pon1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371-92.
40. Senti M, Aubo C, Tomas M. Differential effects of smoking on myocardial infarction risk according to the gln/arg 192 variants of the human paraoxonase gene. Metabolism 2000;49: 557-9.
41. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mrna levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-15.
42. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory hdl becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
43. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation 2003; 107: 2775-9.
44. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, van der Graaf Y. Paraoxonase variants relate to 10-year risk in coronary artery disease: Impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 2009; 54: 1238-45.
45. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008; 66: 366-74.
46. Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001; 34: 475-81.
47. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98: 883-5.